Joshua D Brody

16PUBLICATIONS
117CO-AUTHORS
Medical devicesHaematological tumoursAllergyTumour immunologyAvionics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Apr 29, 2026
mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.

|Jul 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Taylor R Brooks, Emily C Zabor, Yohanna B Bedelu

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Jan 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

Joshua D Brody, Judit Jørgensen, David Belada

|Mar 26, 2024
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz

|Jan 31, 2024
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors.

Anthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy

Pageof 3

Frequent Collaborators

3 joint publications

Brian D Brown

3 joint publications

Yasmin H Karimi

3 joint publications

Miriam Merad

2 joint publications

Nancy L Bartlett